The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Open accessAbstract
Transfected siRNAs regulate numerous transcripts sharing limited complementarity to the RNA duplex. This unintended (“off-target”) silencing can hinder the use of RNAi to define gene function. Here we describe position-specific, sequence-independent chemical modifications that reduced silencing of partially complementary transcripts by all siRNAs tested. Silencing of perfectly matched targets was unaffected by these modifications. The chemical modification also reduced off-target phenotypes in growth inhibition studies. Key to the modification was 2′-O-methyl ribosyl substitution at position 2 in the guide strand, which reduced silencing of most off-target transcripts with complementarity to the seed region of the siRNA guide strand. The sharp position dependence of 2′-O-methyl ribosyl modification contrasts with the broader position dependence of base-pair substitutions within the seed region, suggesting a role for position 2 of the guide strand distinct from its effects on pairing to target transcripts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
Improved tools for biological sequence comparison.
Pearson, W. R., & Lipman, D. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.8.2444 · Cited by 11,227
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Self-citationAsymmetry in the Assembly of the RNAi Enzyme Complex
Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370
Self-citationSpecificity of microRNA target selection in translational repression
Doench, J. G., & Sharp, P. A. (2004) · Genes & Development · doi:10.1101/gad.1184404 · Cited by 1,636
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate
Elbashir, S. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6877 · Cited by 1,449
Regulation by let-7 and lin-4 miRNAs Results in Target mRNA Degradation
Bagga, S., Bracht, J., Hunter, S., Massirer, K., Holtz, J., Eachus, R., & Pasquinelli, A. E. (2005) · Cell · doi:10.1016/j.cell.2005.07.031 · Cited by 1,346
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer
Hughes, T. R., Mao, M., Jones, A. R., Burchard, J., Marton, M. J., Shannon, K. W., Lefkowitz, S. M., Ziman, M., Schelter, J. M., Meyer, M. R., et al. (2001) · Nature Biotechnology · doi:10.1038/86730 · Cited by 1,298
Self-citationATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway
Nykänen, A., Haley, B., & Zamore, P. D. (2001) · Cell · doi:10.1016/s0092-8674(01)00547-5 · Cited by 1,016
Cited by
Predicting effective microRNA target sites in mammalian mRNAs
Agarwal, V., Bell, G. W., Nam, J.-W., & Bartel, D. P. (2015) · eLife · doi:10.7554/elife.05005 · Cited by 7,318
“…1—figure supplement 1B , Figure 3 , Figure 3—figure supplement 1B,C , Figure 4 ( Lim et al., 2005 ; Birmingham et al., 2006 ; Schwarz et al., 2006 ; Jackson et al., 2006a ; Jackson et al., 2006b ; Grimson et al., 2007 ; Anderson et al., 2008 ) Figure 1—figure supplement 1C GSM95614, GSM95615,…”
BackgroundInfluentialKnocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis
Legnini, I., Di Timoteo, G., Rossi, F., Morlando, M., Briganti, F., Sthandier, O., Fatica, A., Santini, T., Andronache, A., Wade, M., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.02.017 · Cited by 2,173
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Self-citationInterfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Illuminating the silence: understanding the structure and function of small RNAs
Rana, T. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2085 · Cited by 1,083
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Self-citationRNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication
Karlas, A., Machuy, N., Shin, Y., Pleissner, K.-P., Artarini, A., Heuer, D., Becker, D., Khalil, H., Ogilvie, L. A., Hess, S., et al. (2010) · Nature · doi:10.1038/nature08760 · Cited by 695
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
siRNA vs. shRNA: Similarities and differences
Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 660
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Expanding the MicroRNA Targeting Code: Functional Sites with Centered Pairing
Shin, C., Nam, J.-W., Farh, K. K.-H., Chiang, H. R., Shkumatava, A., & Bartel, D. P. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.005 · Cited by 611
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex
Wang, Y., Juranek, S., Li, H., Sheng, G., Tuschl, T., & Patel, D. J. (2008) · Nature · doi:10.1038/nature07666 · Cited by 577
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs
Khan, A. A., Betel, D., Miller, M. L., Sander, C., Leslie, C. S., & Marks, D. S. (2009) · Nature Biotechnology · doi:10.1038/nbt.1543 · Cited by 534
Off-target effects by siRNA can induce toxic phenotype
Fedorov, Y., Anderson, E. M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W. S., & Khvorova, A. (2006) · RNA · doi:10.1261/rna.28106 · Cited by 490
Self-citationMukhopadhyay, S., Wen, X., Ratti, N., Loktev, A., Rangell, L., Scales, S. J., & Jackson, P. K. (2013) · Cell · doi:10.1016/j.cell.2012.12.026 · Cited by 486
The art and design of genetic screens: RNA interference
Boutros, M., & Ahringer, J. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2364 · Cited by 474
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Mukhopadhyay, S., Wen, X., Chih, B., Nelson, C. D., Lane, W. S., Scales, S. J., & Jackson, P. K. (2010) · Genes & Development · doi:10.1101/gad.1966210 · Cited by 435
Nonviral delivery of synthetic siRNAs in vivo
Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Chemically modified siRNA: tools and applications
Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431
Pharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
Identification of genes that regulate epithelial cell migration using an siRNA screening approach
Simpson, K. J., Selfors, L. M., Bui, J., Reynolds, A., Leake, D., Khvorova, A., & Brugge, J. S. (2008) · Nature Cell Biology · doi:10.1038/ncb1762 · Cited by 406
Self-citationDeterminants of targeting by endogenous and exogenous microRNAs and siRNAs
Nielsen, C. B., Shomron, N., Sandberg, R., Hornstein, E., Kitzman, J., & Burge, C. B. (2007) · RNA · doi:10.1261/rna.768207 · Cited by 384
Toward MicroRNA–Based Therapeutics for Heart Disease: The Sense in Antisense
van Rooij, E., Marshall, W. S., & Olson, E. N. (2008) · Circulation Research · doi:10.1161/circresaha.108.183426 · Cited by 377
Self-citationDistance constraints between microRNA target sites dictate efficacy and cooperativity
Sætrom, P., Heale, B. S. E., Snøve, O., Aagaard, L., Alluin, J., & Rossi, J. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm133 · Cited by 375
Bramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjær, N., Babu, B. R., Højland, T., Abramov, M., Van Aerschot, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp106 · Cited by 369
A review of nanocarriers for the delivery of small interfering RNA
Kesharwani, P., Gajbhiye, V., & Jain, N. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.068 · Cited by 368
Double-Stranded RNA Technology to Control Insect Pests: Current Status and Challenges
Christiaens, O., Whyard, S., Vélez, A. M., & Smagghe, G. (2020) · Frontiers in Plant Science · doi:10.3389/fpls.2020.00451 · Cited by 339
RNA Interference: From Basic Research to Therapeutic Applications
Kurreck, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802092 · Cited by 335
Milk exosomes - Natural nanoparticles for siRNA delivery
Aqil, F., Munagala, R., Jeyabalan, J., Agrawal, A. K., Kyakulaga, A.-H., Wilcher, S. A., & Gupta, R. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.011 · Cited by 314
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
Rubinstein, A. D., Eisenstein, M., Ber, Y., Bialik, S., & Kimchi, A. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.10.014 · Cited by 302
On the art of identifying effective and specific siRNAs
Pei, Y., & Tuschl, T. (2006) · Nature Methods · doi:10.1038/nmeth911 · Cited by 302
Deng, Y., Wang, C. C., Choy, K. W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T. K. H., & Tang, T. (2014) · Gene · doi:10.1016/j.gene.2013.12.019 · Cited by 301
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
Recent progress in non-native nucleic acid modifications
McKenzie, L. K., El-Khoury, R., Thorpe, J. D., Damha, M. J., & Hollenstein, M. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01430c · Cited by 300
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Wooddell, C. I., Rozema, D. B., Hossbach, M., John, M., Hamilton, H. L., Chu, Q., Hegge, J. O., Klein, J. J., Wakefield, D. H., Oropeza, C. E., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.31 · Cited by 293
Chemical modification: the key to clinical application of RNA interference?
Corey, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33483 · Cited by 285
RNAi‐based therapeutics–current status, challenges and prospects
Tiemann, K., & Rossi, J. J. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900023 · Cited by 283
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
Self-citationAction and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 279
Heme oxygenase-1 in tumor biology and therapy
Was, H., Dulak, J., & Jozkowicz, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011551 · Cited by 259
Partial DNA-guided Cas9 enables genome editing with reduced off-target activity
Yin, H., Song, C.-Q., Suresh, S., Kwan, S.-Y., Wu, Q., Walsh, S., Ding, J., Bogorad, R. L., Zhu, L. J., Wolfe, S. A., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2559 · Cited by 240
An RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229
Tubby family proteins are adapters for ciliary trafficking of integral membrane proteins
Badgandi, H. B., Hwang, S.-H., Shimada, I. S., Loriot, E., & Mukhopadhyay, S. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201607095 · Cited by 182
Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo
Hassler, M. R., Turanov, A. A., Alterman, J. F., Haraszti, R. A., Coles, A. H., Osborn, M. F., Echeverria, D., Nikan, M., Salomon, W. E., Roux, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky037 · Cited by 181
Self-citationChen, P. Y., Weinmann, L., Gaidatzis, D., Pei, Y., Zavolan, M., Tuschl, T., & Meister, G. (2008) · RNA · doi:10.1261/rna.789808 · Cited by 176
In vivo delivery of RNAi with lipid-based nanoparticles
Huang, L., & Liu, Y. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124709 · Cited by 174
Molina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157
“This effect is more statistically significant using siRNAs that have been chemically modified to reduce off-target effects (OTP (15)) and indicates that most of the KRAS mutant cell lines in this panel show some evidence of RAS oncogene addiction.”
Kanatani, S., Yozu, M., Tabata, H., & Nakajima, K. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2132-08.2008 · Cited by 163
Pal, K., Hwang, S.-H., Somatilaka, B., Badgandi, H., Jackson, P. K., DeFea, K., & Mukhopadhyay, S. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201506132 · Cited by 141
“MEFs were assayed within four or five passages in culture. siRNA transfection The siRNAs for mouse Chc and Grks were predesigned On-target Plus (OTP) siRNA duplexes shown to yield a reduced frequency of off-target effects (GE Healthcare; Jackson et al., 2006).”
MethodMcManus, K. J., Barrett, I. J., Nouhi, Y., & Hieter, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813414106 · Cited by 133
New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer
Yamato, K., Yamada, T., Kizaki, M., Ui-Tei, K., Natori, Y., Fujino, M., Nishihara, T., Ikeda, Y., Nasu, Y., Saigo, K., et al. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701118 · Cited by 110
Optimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles
Haraszti, R. A., Miller, R., Didiot, M.-C., Biscans, A., Alterman, J. F., Hassler, M. R., Roux, L., Echeverria, D., Sapp, E., DiFiglia, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.024 · Cited by 107
Self-citationDevelopment of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
MicroRNA 486 is a potentially novel target for the treatment of spinal cord injury
Jee, M. K., Jung, J. S., Choi, J. I., Jang, J. A., Kang, K. S., Im, Y. B., & Kang, S. K. (2012) · Brain · doi:10.1093/brain/aws047 · Cited by 91
Multiplexing siRNAs to compress RNAi-based screen size in human cells
Martin, S. E., Jones, T. L., Thomas, C. L., Lorenzi, P. L., Nguyen, D. A., Runfola, T., Gunsior, M., Weinstein, J. N., Goldsmith, P. K., Lader, E., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm141 · Cited by 40
Thermodynamic Control of Small RNA-Mediated Gene Silencing
Ui-Tei, K., Nishi, K., Takahashi, T., & Nagasawa, T. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00101 · Cited by 31
“2′-O-methyl modification of the guide strand seed region alters the RISC conformation and reduces seed-dependent off-target effects by dissociating off-target transcripts with weak binding to the guide strand (Jackson et al., 2006b).”
InfluentialPandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Stie, J., & Fox, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049402 · Cited by 12
Metadata
- Authors
- Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., Marshall, W., Khvorova, A., & Linsley, P. S.
- Venue
- RNA
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2006-05-08
- Volume
- 12
- Issue
- 7
- Pages
- 1197-1205
- ISSN
- 1355-8382 (ISSN-L)
- 1469-9001
- OpenAlex
- W2143313350
- Cited by
- 789
- References
- 29
- FWCI
- 24.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.